Recent insider trends for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) have caught the attention of investors. Analysts study insider data to get a sense of sense of what key shareholders think about the outlook for a particular stock. In the case of ANTH, the data has some interesting implications for where the stock might be headed.
Institutions own 20.75% of Anthera Pharmaceuticals, Inc. (ANTH)’s shares. The total value of these holdings, in millions, is $5. Among active positions in the latest quarter, 16 holders increased their positions by a total of 689941 shares, 30 holders decreased the positions by a total of 905250 shares, and 6 holders held their positions. This works out to a net decrease in ownership of 215309 shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 5 holders initiated new positions by a total of 89237 shares and 16 holders exited their positions by a total of 303081 shares. This nets out to a decrease of 213844 shares and is another bearish sign for ANTH.
In the last three months, insiders executed a total of 2 trades. 2 of these were buys. Insider ownership increased by a total of 13550 shares, which suggests that ANTH’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 2 buys, and ownership increased by a net of 13550 shares.
Short interest is another tool that analysts use to gauge investor sentiment. It represents the number of a stock’s shares that are being shorted by investors. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)’s short interest is 1.38 million shares, or % of the float. This represents an increase of 1% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
In light of the insider ownership and trading data it makes sense to consider technicals to see if they come to a similar conclusion about the outlook for ANTH. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that ANTH is a Strong buy, which implies that ANTH is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) is undervalued.